|
KMID : 0911820210220020043
|
|
Korean Journal of Headache
2021 Volume.22 No. 2 p.43 ~ p.48
|
|
|
Lasmiditan: Another Therapeutic Option for Acute Migraine Treatment
|
|
Park Hong-Kyun
|
|
|
Abstract
|
|
|
|
Lasmiditan, a selective 5-hydroytryptamine 1F (5-HT 1F) receptor agonist, is the first drug that was approved by the US Food and Drug Administration for the acute treatment of migraine in adults in 2019. Two phase III trials demonstrated a better efficacy of achieving headache freedom within 2 hours after dosing compared to placebo. Approximately 40% of the patients with lasmiditan experienced freedom from the most bothersome symptom than those with placebo. Most common adverse effects were dizziness, somnolence, and paresthesia with mild to moderate severity, which might be related to the penetration of lasmiditan to central nervous system. Open-label long-term study also showed similar profiles regarding safety, tolerability, and efficacy of lasmiditan. Lasmiditan might be used for patients with previous cardiovascular diseases because of lacking properties of vasoconstriction. This review article summarized the results of recent lasmiditan-related clinical trials, and provide opinions about the use of lasmiditan for acute migraine treatment in clinical practice.
|
|
|
KEYWORD
|
|
|
5-HT 1F receptor, Ditan, Lasmiditan, Migraine, Headache
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|